BIOGRAPHICAL SKETCH

Academic & Professional Background

• B.A. (Natural Science) 1957 - Cambridge University, Cambridge, England
• M.B., B.Ch. (Medicine) 1960 - Cambridge University, Cambridge, England
• M.R.C.P. (Medicine) 1963 - Guy's Hospital, London England
• M.A. 1965 - Cambridge University, Cambridge, England
• Ph.D. (Cell Biology) 1970 - University of Chicago, Chicago, Illinois
• M.D. 1972 - (Flex, Illinois)
• F.A.C.P. 1980
• F.R.C.P. (Medicine) 1984 - London, England

Current Research Interests

• Bronchodilators
• Clinical Trials in COPD
• Pharmacology of the Airways
• Pulmonary Surfactant
• Radiation Effects on Lungs

Selected Publications

Gross NJ. Extrapulmonary effects of chronic obstructive pulmonoary disease. Current Opinion in Pulmonary Medicine 7:84-92, 2001.

Gross NJ, Kellam M, Young J, Krishnasamy S, Dhand R. Separation of alveolar surfactant into subtypes: A comparison of methods. Am J Respir Cri Care Med 152:617-622, 2000.

Niewoehner DE, Erbland ML, Dupree RH, Gross NJ, et al. A randomized trial of systemic corticosteroids for exacerbations of chronic obstructive pulmonary disease. N Engl J Med (May), 1999.

Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases of patients with stable COPD, comparison with albuterol and ipratropium. Am J Respir Crit Care Med (in press), 1999.

Gross NJ. Anticholinergic agents as bronchodilators. In: "Anticholinergic Drugs" Ed S. Spector, Lung Biology in Health and Disease, Marcel Dekker, Inc., NY, 1999.

Sorresso D, Gross NJ. COPD Management. Conn's Current Therapy. WB Saunders Co., Philadelphia pp. 178-182, 1999.

Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, et al. Efficacy of Salmeterol xinafoate in the treatment of COPD. Chest 115:957, 1999.

Gross NJ. Leukotriene modifiers: Role in asthma management. J Respir Dis 19:245-261, 1998.

Krishnasamy S, Teng AL, Dhand R, Schultz RM, Gross NJ. Molecular cloning, characterization, and differential expression pattern of mouse lung surfactant convertase. Am J Physiol 275:L969-L975, 1998.

Alpha-1-Antitrypsin Registry Group. Survival and FEV-1 decline in individuals with severe deficiency of alpha-1-antitrypsin. Am J Respir Crit Care Med 158:49-59, 1998.

Gross NJ, Tashkin D, Miller R, Oren J, Coleman W, Lindberg S. Inhalation by nebulization of albuterol-ipratropium combination (Dey Combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration 65:354-362, 1998.

Gross NJ. New high-dose inhaled steroids. J Respir Dis 18:690-705, 1997.

Gross NJ, Veldhuizen R, Possmayer F, Dhand R. Surfactant convertase is not essential for surfactant film formation. Am J Physiol 273:L907-L912, 1997.

Combivent Inhalation Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 112:1514-1521, 1997.

Gross NJ. COPD management: Setting therapeutic goals. J Respir Dis 17:92-100, 1996.

Gross NJ. COPD management: Achieving bronchodilation. J Respir Dis 17:183-95, 1996.

Gross NJ. COPD management: Infection and inflammation. J Respir Dis 17:220-25, 1996.

Navin DM, Gross NJ. Management of COPD. Current Opinion in Pulmonary Med 2:141-147, 1996.

Nonn RA, Gross NJ. Effect of radiation on the lungs. Current Opinion in Pulmonary Med 2:390-395, 1996.

Gross NJ. COPD management: The question of steroids. J Respir Dis 17:299-304, 1996.

Gross NJ. COPD management: Options for patients with severe disease. J Respir Dis 17:494-501, 1996.

Gross NJ, Bublys V, D'Anza J, Brown CC. The role of alpha 1-antritrypsin in control of surfactant metabolism. Am J Physiol, Lung Cell 12:L438-L445, 1995.

Gross NJ. Extracellular metabolism of lung surfactant. Ann Rev Physiol 57:135-150, 1995.

Gross NJ. Airway inflammation in COPD. Chest 107:210-213S, 1995.

Gross NJ. Pulmonary surfactant; unanswered questions. Thorax 50:325-327, 1995.

Gross NJ. The Lung Health Study: Disappointment and triumph. JAMA 272:1539-41, 1994.

Projects Completed or Active (Selected)

• Molecular Biology of Surfactant Convertase
• Bronchodilator Studies
• Corticosteroids in Acute COPD
• Registry of Patients with Alpha-1 Anti-Trypsin Deficiency
• Pharmacodynamic Dose-Response Pilot Study of Ipratropium Bromide in Patients with COPD
• Randomized, Double-Blind, Double-Dummy Comparative Clinical Trial Twelve Week Courses of Salmeterol Xinafoate vs Ipratropium Bromide vs Placebo

Research Funding Sources

• Boerhinger Ingelheim
• Dey Labs
• DuPont Pharmaceuticals
• Glaxo
• Merck, Inc.
• Miles-Bayer
• National Institutes of Health
• Novartis
• Sepracor
• SmithKline Beecham
• VA Cooperative Study
• VA Merit Review

Research Methods Employed

• Cell Biology Techniques
• Clinical Studies
• Molecular Biology Techniques
• Pulmonary Function Tests

Professional Accomplishments

• 1998-2001 - U.S. Food and Drug Administration, Pulmonary and Allergy Advisory Committee
• 1996 - Member, Editorial Board, American Journal of Respiratory and Critical Care Medicine
• 1990 - U.S. Pharmacopea, Pulmonary and Allergy Committee
• 1985-1988 - Board of Directors, American Thoracic Society
• 1984 - Fellow, Royal College of Physicians
• 1983 - President, Chicago Lung Association
• 1980 - Fellow, American College of Physicians
• 1980 - President, IL Chapter ACCP
• 1964 - Fulbright Scholar